Clinical Updates on Immunotherapy
Dr. Yabing Cao was invited to give a lecture about the latest clinical updates on immune therapy for NSCLC in the educational forum held by Hanzhong 3201 hospital in central Shanxi, China.
Hong Kong Immune Oncology Symposium
Hong Kong Immuno-Oncology symposium. Dr. Yilong Wu, Dr. Solange Peters, and Dr. Yabing Cao shared opinions on ALK positive NSCLC.
Elaine’s group discovered a cardiac glycoside restrains EGFR-related and EGFR-independent NSCLC cell proliferation with distinct treatment mechanism
Non-small cell lung cancer (NSCLC) is the predominant histological type of lung cancer and is characterized by the highest mortality and incidence rates among these types of malignancies (1, 2). Traditional Chinese medicine (TCM) has been applied for centuries in China (3, 4). Cardiac glycosides, a class of natural products, have been identified as a potential type of chemotherapeutic agent (5, 6).
Gossypol inhibits non-small cell lung cancer cells proliferation by targeting EGFRL858R/T790M
Dr Elaine Lai Han Leunget al reported thatGossypol inhibits non-small cell lung cancer cells proliferation by targeting EGFRL858R/T790M